ES2195655T3 - Procedimiento para tratar fiebre hemorragica virica con proteina c. - Google Patents

Procedimiento para tratar fiebre hemorragica virica con proteina c.

Info

Publication number
ES2195655T3
ES2195655T3 ES99965808T ES99965808T ES2195655T3 ES 2195655 T3 ES2195655 T3 ES 2195655T3 ES 99965808 T ES99965808 T ES 99965808T ES 99965808 T ES99965808 T ES 99965808T ES 2195655 T3 ES2195655 T3 ES 2195655T3
Authority
ES
Spain
Prior art keywords
protein
fever
hemorragical
viric
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99965808T
Other languages
English (en)
Spanish (es)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2195655T3 publication Critical patent/ES2195655T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES99965808T 1998-11-20 1999-11-15 Procedimiento para tratar fiebre hemorragica virica con proteina c. Expired - Lifetime ES2195655T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20

Publications (1)

Publication Number Publication Date
ES2195655T3 true ES2195655T3 (es) 2003-12-01

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99965808T Expired - Lifetime ES2195655T3 (es) 1998-11-20 1999-11-15 Procedimiento para tratar fiebre hemorragica virica con proteina c.

Country Status (12)

Country Link
US (2) US6270764B1 (enExample)
EP (1) EP1131091B1 (enExample)
JP (1) JP2002530353A (enExample)
CN (1) CN1326356A (enExample)
AT (1) ATE235915T1 (enExample)
AU (1) AU2149800A (enExample)
BR (1) BR9915460A (enExample)
CA (1) CA2351470A1 (enExample)
DE (1) DE69906568T2 (enExample)
ES (1) ES2195655T3 (enExample)
IL (1) IL142220A0 (enExample)
WO (1) WO2000030677A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
BR0213293A (pt) 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
US20200093853A1 (en) * 2016-12-08 2020-03-26 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ZA983497B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体

Also Published As

Publication number Publication date
ATE235915T1 (de) 2003-04-15
DE69906568T2 (de) 2004-02-12
US6767539B2 (en) 2004-07-27
DE69906568D1 (de) 2003-05-08
US20010028880A1 (en) 2001-10-11
CN1326356A (zh) 2001-12-12
CA2351470A1 (en) 2000-06-02
US6270764B1 (en) 2001-08-07
EP1131091A1 (en) 2001-09-12
WO2000030677A1 (en) 2000-06-02
IL142220A0 (en) 2002-03-10
AU2149800A (en) 2000-06-13
JP2002530353A (ja) 2002-09-17
BR9915460A (pt) 2001-07-17
EP1131091B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
PT912176E (pt) Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao
TR200000782T2 (tr) Resorsinol türevleri.
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
ES2124461T3 (es) Derivados de oxalilamino-benzofurano y de benzotienilo.
ES520340A0 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas.
EA199800667A1 (ru) Новые фенантридины
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA200000978A1 (ru) Противоопухолевая композиция, содержащая синергическую комбинацию производного антрациклина и производного камптотецина
PT1300084E (pt) Composicaio para o tratamento de insuficiencias venosas cronicas melha.
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE215084T1 (de) Imidazopyridin-azolidinone
DK0571457T3 (da) Iloprost med virkning overfor cerebral malaria.
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
BR9915984A (pt) Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica